The FDA has decided to limit the use of the COVID-19 vaccine to individuals at least 18 years old who cannot receive other authorized or approved COVID-19 vaccines. The agency also will authorize its use for individuals who would “otherwise not receive a COVID-19 vaccine.” FDA came to the conclusion after reviewing data related to…
FDA sends warning letters to CBD and delta-8 THC product vendors
The FDA has issued warning letters to several companies selling products with cannabidiol (CBD) and delta-8 tetrahydrocannabinol (delta-8 THC) in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). While the agency has previously sent out warnings to firms selling CBD-related products from 2015 to 2022, it is the first time it has sent…
Pfizer recalls certain lots of blood-pressure drug Accupril
Pfizer (NYSE:PFE) has announced a voluntary recall of five lots of Accupril (Quinapril HCl) tablets owing to elevated levels of the nitrosamine N-nitroso-quinapril. Accupril, an angiotensin-converting enzyme (ACE) inhibitor, is indicated for treating hypertension. FDA has also approved its use as an adjunctive therapy for treating heart failure. N-nitroso-quinapril, which can be frequently found in…
CMS will limit coverage of Aduhelm to people in clinical trials
The Centers for Medicare & Medicaid Services (CMS) released a national policy regarding coverage for Aduhelm (aducanumab). Controversy has surrounded the Alzheimer’s drug Aduhelm from Biogen (NSDQ:BIIB) and Eisai (TYO:4523) since the FDA’s fast track approval last year. Three members of an FDA advisory committee resigned after the approval. About a week later, nonprofit watchdog group Public Citizen called for high-profile resignations of…
FDA approves Novartis’ Vijoice for to treat rare PROS genetic diseases
Novartis announced that it received FDA approval for its Vijoice (alpelisib) PIK3CA-Related Overgrowth Spectrum (PROS) treatment. Basel, Switzerland-based Novartis said in a news release that Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowth in blood vessel anomalies. FDA approval followed real-world evidence from the EPIK-P1 retrospective chart…
FDA clears antibiotic-embedded hernia mesh for fighting implant infections
Ariste Medical recently won FDA 510(k) clearance for its drug-embedded, polypropylene hernia mesh to fight microbial colonization. The Salt Lake City-based drug-device developer said the patents and proprietary formulations behind the technology could prevent infection, inflammation or clotting associated with implants. Ariste’s synthetic mesh carries two antibiotics — minocycline and rifampin — to prevent contamination…
Herbal supplements recalled as a result of undeclared sildenafil and tadalafil
Amazon appears to have growing troubles around herbal supplements sold on its site. The online retail giant has informed the herbal supplement company Celebrate Today (Brentwood, New York) that its Red Mammoth pills were tainted with sildenafil and tadalafil, both of which are FDA-regulated drugs for erectile dysfunction and other conditions. Similarly, Amazon announced that…
FDA fully approves Moderna’s COVID-19 vaccine
Moderna (NSDQ:MRNA) announced today that it received full FDA approval of the biologics license application for its COVID-19 vaccine. FDA’s approval for the company’s Spikevax mRNA COVID-19 vaccine covers the prevention of the virus in individuals aged 18 years or older. Moderna submitted for full FDA approval back in June 2021 and becomes the second…
FDA postpones some inspectional activities amid omicron surge
The FDA announced earlier this week that it made some temporary changes to its inspectional activities due to COVID-19. With the omicron variant of the virus causing surges across the world, the FDA implemented the changes in the U.S. on Dec. 29, 2021, to ensure the safety of its employees and the firms it regulates,…
Federal judge throws out Purdue Pharma’s opioid settlement that protected Sackler family
Colleen McMahon of the U.S. District Court for the Southern District of New York overturned a sweeping settlement against Purdue Pharma over its role in the opioid crisis. Purdue’s Oxycontin (oxycodone) is among the most widely used opioids. In September, Judge Robert Drain of the U.S. Bankruptcy Court in White Plains, New York, authorized a…